普伐他汀辅助强化抗血小板方案治疗急性脑梗死临床疗效观察

Clinical curative effect of pravastatin assisted intensive antiplatelet regimen in the treatment of acute cerebral infarction

研究普伐他汀辅助强化抗血小板方案治疗急性脑梗死的临床疗效及安全性,将急性脑梗死患者130例分为观察组和对照组,每组各65例。两组患者均接受脑梗死常规治疗,对照组服用普伐他汀和阿司匹林,观察组服用普伐他汀、阿司匹林和氯毗格雷,每日一次,两组患者均连续治疗两周。检测和记录患者治疗前后血脂水平及炎症因子水平变化,并用NIHSS评分评估临床疗效。结果显示,观察组血脂水平及炎症因子水平和NIHSS评分显著低于对照组。因此,普伐他汀辅助强化抗血小板方案可以明显提高急性脑梗死患者的临床疗效,降低血脂和炎症因子水平,改善神经功能缺损,安全性较好。

To observe the clinical efficacy and safety of pravastatin assisted intensive antiplatelet regimen in the treatment of acute cerebral infarction, 130 patients with acute cerebral infarction treated were divided into observation group and the control group （ n =65）. Both groups received routine treatment for cerebral infarction. The control group received pravastatin and aspirin. The observation group received pravastatin, aspirin and clopidogrel once daily. Both groups received continuous treatment for two weeks. The clinical efficacy, blood lipid level and inflammatory factors were recorded. The results showed that the levels of blood lipid, inflammatory factors and the NIHSS score of clinical efficacy in the observation group were lower than those of the control group. Thus, Pravastatin assisted antiplatelet therapy can obviously improve the clinical efficacy of patients with acute cerebral infarction, reduce the level of blood lipid and inflammatory factors, improve the nerve function, and have better safety.